Advanced search
Publication Cover
OncoImmunology Volume 3, 2014 - Issue 12
Submit an article Journal homepage
557
Views
3
CrossRef citations to date
0
Altmetric
Author's View

Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia

Marvin M van LuijnDepartment of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center; Amsterdam, The Netherlands;Department of Immunology; Erasmus MC University Medical Center; Rotterdam, The Netherlands
,
Willemijn van den AnckerDepartment of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center; Amsterdam, The Netherlands
,
S Marieke van HamDepartment of Immunopathology; Sanquin Research and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam, The Netherlands
&
Arjan A van de LoosdrechtDepartment of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center; Amsterdam, The NetherlandsCorrespondence[email protected]
Article: e941737 | Received 30 May 2014, Accepted 03 Jun 2014, Published online: 31 Oct 2014

References

  • Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJM, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013; 31:3889-97; PMID: 24062400; http://dx.doi.org/10.1200/JCO.2012.45.9628
  • Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat RevImmunol 2006; 6:715-727; PMID: 16977338; http://dx.doi.org/10.1038/nri1936
  • Teague RM and Kline J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J Immunother Cancer 2013; 1; PMID: 24353898; http://dx.doi.org/10.1186/2051-1426-1-13
  • Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID: 20525992; http://dx.doi.org/10.1056/NEJMoa1003466
  • van Luijn MM, van den Ancker W, Chamuleau ME, Zevenbergen A, Westers TM, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells. Cancer Res 2011; 71:2507-17; PMID: 21310823; http://dx.doi.org/10.1158/0008-5472.CAN-10-3689
  • van Luijn MM, van de Loosdrecht AA, Lampen MH, van Veelen PA, Zevenbergen A, Kester MG, de Ru AH, Ossenkoppele GJ, van Hall T, van Ham SM. Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells. PLoS One 2012; 7:e34649; PMID: 22563374; http://dx.doi.org/10.1371/journal.pone.0034649
  • van den Ancker W, van Luijn MM, Chamuleau ME, Kelder A, Feller N, Terwijn M, Zevenbergen A, Schuurhuis GJ, Ham SM, Westers TM, et al. High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia. Leuk Res 2014; 38:691-93; PMID: 24731748; http://dx.doi.org/10.1016/j.leukres.2014.03.014
  • Chamuleau ME, van de Loosdrecht AA, Hess CJ, Janssen JJ, Zevenbergen A, Delwel R, Valk PJM, Löwenberg B, Ossenkoppele GJ. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 2008; 93:1894-98; PMID: 19050070; http://dx.doi.org/10.3324/haematol.13113
  • Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013; 25:261-267; PMID: 23579076; http://dx.doi.org/10.1016/j.coi.2013.03.004
  • van Kasteren SI, Overkleeft H, Ovaa H, Neefjes J. Chemical biology of antigen presentation by MHC molecules. Curr Opin Immunol 2014; 26:21-31; PMID: 24556397; http://dx.doi.org/10.1016/j.coi.2013.10.005

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.